Article Text

Download PDFPDF
Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia–dysplasia–adenocarcinoma sequence
  1. Stephen Hayes,
  2. Sajad Ahmed,
  3. Peter Clark
  1. Department of Histopathology, Salford Royal NHS Foundation Trust, Salford, UK
  1. Correspondence to Dr Stephen Hayes, Salford Royal NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK; stephen.hayes{at}


Background Barrett oesophagus (BO) occurs as a consequence of prolonged gastro-oesophageal reflux and it may precede the development of oesophageal adenocarcinoma.

Aims The aim of this study was to accurately assess Cdx2 expression in the oesophageal metaplasia–dysplasia–adenocarcinoma sequence.

Method The expression of the transcription factor Cdx2 in Barrett metaplasia, high-grade glandular dysplasia and adenocarcinoma was investigated using immunohistochemistry.

Results The results confirmed previous immunohistochemistry and PCR-based investigations, indicating that Cdx2 was expressed by intestinal metaplasia in the oesophagus. In addition, upregulation followed by linear downregulation of Cdx2 expression through the oesophageal metaplasia–dysplasia–adenocarcinoma sequence was demonstrated for the first time.

Conclusion Such downregulation of Cdx2 expression could be in keeping with a role as a tumour suppressor gene, but a simpler explanation would be downregulation of a differentiation marker.

  • Barrett oesophagus
  • cancer
  • immunocytochemistry

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None to declare.

  • Ethics approval This study was conducted with the approval of the Northern Manchester Local Research Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.